Table 2.
Variables | Disease-specific survival | ||
---|---|---|---|
HR | 95% CI | P | |
Univariate analysis | |||
Age (≤60 vs > 60 years) | 0.923 | 0.562 - 1.516 | 0.753 |
Gender (male vs female) | 0.697 | 0.407 - 1.195 | 0.190 |
Tumor stage (Ta-T1 vs T2-T4) | 5,401 | 2.321 - 12.568 | <0.001 |
Grade (G1- G2 vs G3) | 4,237 | 2.203 - 8.150 | <0.001 |
Lymph node metastasis (yes vs no) | 4,884 | 2.832 - 8.422 | <0.001 |
HOTAIR expression > 75% (high vs low) | 2,033 | 1.180 - 3.501 | 0.011 |
Multivariate analysis | |||
Stage (T2-T4) | 2,654 | 1.021 - 6.856 | 0.045 |
Grade (G3) | 2,327 | 1.115 - 4.854 | 0.024 |
Lymph node metastasis (N+) | 2,951 | 1.661 - 5.242 | <0.001 |
HOTAIR expression (>75%) | 2,200 | 1.232 - 3.928 | 0.008 |
Abbreviations: DSS- disease-specific survival; HR hazard ratio, CI confidence interval.
Patients were dichotomised according to their HOTAIR expression level (group 1 = 25% of patients with highest HOTAIR expression, group 2 = 75% of patients with average or low HOTAIR expression).